期刊文献+

重组腺病毒Ad-人基质金属蛋白酶1体外转染大鼠BMSCs研究 被引量:4

RECOMBINANT ADENOVIRUS Ad-HUMAN MATRIX METALLOPROTEINASE 1 TRANSFECTING BONE MARROW MESENCHYMAL STEM CELLS OF RATS IN VITRO
原文传递
导出
摘要 目的利用重组腺病毒Ad-人基质金属蛋白酶1(human matrix metalloproteinase 1,hMMP-1)体外转染大鼠BMSCs,为BMSCs联合hMMP-1基因移植治疗肝纤维化奠定实验基础。方法取2~3周龄SD大鼠骨髓采用全骨髓贴壁法分离培养BMSCs,传至第3代并进行鉴定;用携带增强绿色荧光蛋白(enhanced green fluorescent protein,EGFP)标记的重组腺病毒Ad-hMMP-1-EGFP体外转染第3代BMSCs,荧光显微镜下观察转染情况,流式细胞仪检测转染效率并确定最佳感染复数(multiplicity of infection,MOI)。实验分为未转染BMSCs组(A组)、Ad-EGFP转染BMSCs组(B组)及Ad-hMMP-1-EGFP转染BMSCs组(C组),采用MTT法检测转染后细胞增殖情况,RT-PCR及Western blot分别检测转染后各组细胞内hMMP-1基因和蛋白表达情况,ELISA法检测上清中蛋白hMMP-1分泌水平,hMMP-1酶活性荧光定量试剂盒测定其活性。结果重组腺病毒转染BMSCs后24 h可见绿色荧光表达,72 h时荧光强度最高,最佳MOI为200。MTT检测示3组细胞均于培养3 d进入对数生长期,6 d后进入平台期;各时间点3组间细胞吸光度(A)值比较,差异均无统计学意义(P>0.05)。RT-PCR、Western blot及ELISA检测示,A、B组均无hMMP-1基因和蛋白表达,C组hMMP-1基因和蛋白均高效表达。荧光定量试剂盒测定A、B组均未检测到hMMP-1酶活性,C组hMMP-1酶活性为1.24 nmol/(mg.min)。结论利用重组腺病毒Ad-hMMP-1成功将外源基因导入大鼠BMSCs并高效表达,为BMSCs联合hMMP-1基因移植治疗肝纤维化奠定了实验基础。 Objective To transfect bone marrow mesenchymal stem cells (BMSCs) of rats by recombinant adenovirus Ad-human matrix metalloproteinase 1 (hMMP-1) in vitro so as to lay the experimental foundation for the treatment of 1 iver fibrosis with a combination of BMSCs and hMMP- 1 gene transplantation. Methods BMSCs were isolated from bone marrow of 2-3 weeks old Sprague Dawley rats by whole bone marrow adherence method and identified, then transfected by recombinant adenovirus Ad-hMMP-1 carrying enhanced green fluorescent protein (EGFP) marker in vitro. The green fluorescent expression was observed by fluorescence microscope and the transfection efficiency was detected by flow cytometry to determine the optimum multiplicity of infection (MOI). BMSCs at passage 3 were divided into 3 groups: untransfected BMSCs group (group A), Ad-EGFP transfected BMSCs group (group B), and Ad-hMMP-1-EGFP transfected BMSCs group (group C); the gene and intracellular protein of hMMP-1 were detected by RT-PCR and Western blot; the ELISA assay was used to detect the supernatant protein expression, and the hMMP-1 activity was measured by fluorescent quantification kit. Results The green fluorescent was observed in BMSCs transfected by recombinant adenovirus at 24 hours after transfection; the fluorescence intensity was highest at 72 hours; and the optimum MOI was 200. The cells of 3 groups entered the logarithmic growth phase on the 3rd day and reached plateau phase on the 6th day by MTT assay; no significant difference was found in the cell proliferation rate among 3 groups (P 〉 0.05). RT-PCR, Western blot, and ELISA assay showed high expressions of the hMMP-1 gene and protein in group C, but no expression in groups A and B. The hMMP-1 activity was 1.24 nmol/(mg.min) in group C, but hMMP-1 activity was not detectable in groups A and B. Conclusion The exogenous hMMP-1 gene is successfully transfected into BMSCs of rats via recombinant adenovirus and can highly express, which lays the experimental foundation for the treatment of liver fibrosis with a combination of BMSCs and hMMP- 1 gene transplantation.
出处 《中国修复重建外科杂志》 CAS CSCD 北大核心 2013年第5期529-534,共6页 Chinese Journal of Reparative and Reconstructive Surgery
关键词 BMSCS 重组腺病毒 基质金属蛋白酶1 基因治疗 大鼠 Bone marrow mesenchymal stem cells Recombinant adenovirus Matrix metalloproteinase 1Gene therapy Rat
  • 相关文献

参考文献21

  • 1lredale JP, Pickering J, Pick J, et al. Mechanisms of spontaneous reso- lution of rat liver fibrosis: Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J C1 in Invest, 1998, 102(3): 538-549.
  • 2杨长青,胡国龄,谭德明,张铮.基质金属蛋白酶-1、反义金属蛋白酶组织抑制因子-1表达质粒对大鼠肝纤维化的影响[J].中华传染病杂志,2000,18(1):29-32. 被引量:29
  • 3Kossakowska AE, Edwards DR, Lee SS, et al. Altered balancebetween matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol, 1998, 153(3): 1895-1902.
  • 4Pardo A, Selman M. MMP-I: the elder of the family. Int I Biochem CeLl Biol, 2005, 37(1): 283-288.
  • 5Cantz T, Manns MP, Ott M. Stem cells in liver regeneration and thera- py. Cell Tissue Res, 2008, 331(1): 271-282.
  • 6Baron F, Gothot A. Mesenchymal stem calls: a new versatile therapeu- tic option. Rev Med Liege, 2007, 62(1): 9-14.
  • 7Minamide A, Yoshida M, Kawakami M, et al. The effects of bone morphogenetic protein and basic fibroblast growth factor on cultured mesenchymal stem cells for spine fusion. Spine (Phila Pa 1976), 2007, 32(10): 1067-1071.
  • 8Franz RW, Shah KJ, Johnson JD, et al. Short-tomid-term results using autologus bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial dis- ease. Vase Endovasular Surg, 2011, 45(5): 398-406.
  • 9Kalka C, Banmgartner I. Gene and stem cell therapy in peripheral arte- rial occlusive disease. Vasc Med, 2008, 13(2): 157-172.
  • 10Ushitora M, Sakurai F, Yamaguchi T, et al. Prevention of hepatic isch- emia-reperfusion injury by pre-administration of catalase-expressing adenovirus vectors. J Control Release, 2010, 142(3): 431-437.

二级参考文献3

共引文献28

同被引文献48

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部